Preventing recurrent events long term after coronary artery bypass graft: Suboptimal use of medications in a population study

American Heart Journal

Volumn 147, Issue 6, 2004, Pages 1047-1053

  Bradshaw, Pamela J ^a,b   Jamrozik, Konrad ^a,c   Gilfillan, Ian ^d   Thompson, Peter L ^a,b  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b SIR CHARLES GAIRDNER HOSPITAL   (Australia)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

^d FREMANTLE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NITRATE; TICLOPIDINE;

ADULT; AGED; ANGINA PECTORIS; ANTICOAGULANT THERAPY; ANTIHYPERTENSIVE THERAPY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CIGARETTE SMOKING; CONFIDENCE INTERVAL; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY BYPASS SURGERY; CORRELATION ANALYSIS; DIABETES MELLITUS; FEMALE; HEALTH SURVEY; HEART FAILURE; HUMAN; HYPERTENSION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RANDOMIZATION; RECURRENT DISEASE; REVIEW; TREATMENT OUTCOME;

EID: 3042852164     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ahj.2003.07.028     Document Type: Article

References (31)

1. ACC/AHA Task Force on Practice Guidelines. ACC/AHA Guidelines Coronary Artery Bypass Graft Surgery. J Am Coll Cardiol. 34:1999;1262-1347
2. Brooks M.M., Jones R.H., Bach R.G., et al. Predictors of mortality and mortality from cardiac causes in the bypass angioplasty revascularization investigation (BARI) randomized trial and registry. Circulation. 101:2000;2682-2689
3. Herlitz J., Caidahl K., Wiklund I., et al. Impact of a history of diabetes on the improvement of symptoms and quality of life during 5 years after coronary artery bypass grafting. J Diabetes Complications. 14:2000;314-321
4. Herlitz J., Sjoland H., Haglid M., et al. Impact of a history of diabetes mellitus on quality of life after coronary artery bypass grafting. Eur J Cardiothorac Surg. 12:1997;853-861
5. Thourani V.H., Weintraub W.S., Stein B., et al. Influence of diabetes mellitus on early and late outcome after coronary artery bypass grafting. Ann Thorac Surg. 67:1999;1045-1052
6. Weintraub W.S., Jones E.L., Craver J.M., et al. Frequency of repeat coronary bypass or coronary angioplasty after coronary artery bypass surgery using saphenous venous grafts. Am J Cardiol. 73:1994;103-112
7. Yusuf S., Zucker D., Peduzzi P., et al. Effect of coronary artery bypass graft surgery on survival overview of 10-year results from the randomised trials by the Coronary Artery Bypass Surgery Trialists Collaboration. Lancet. 344:1994;563-570
8. Bradshaw P.J., Jamrozik K., Le M., et al. Mortality and recurrent cardiac events after CABG long-term outcomes in a population study. Heart. 88:2002;488-494
9. Risk Factor Prevalence Study Management Committee. Risk factor prevalence study: survey no. 3, 1989. 1990;National Heart Foundation of Australia and Australian Institute of Health, Canberra
10. Czarn A.O., Jamrozik K., Hobbs M.S., et al. Follow-up care after acute myocardial infarction. Med J Aust. 157:1992;302-305
11. LaPointe N.M.A., Kramer J.M., DeLong E.R. Patient-reported frequency of taking aspirin in a population with coronary artery disease. Am J Cardiol. 89:2002;1042-1046
12. EUROASPIRE I and II Group. Clinical reality of coronary prevention guidelines a comparison of EUROASPIRE I and II in nine countries. Lancet. 357:2001;995-1001
13. McCallum A.K., Whincup P.H., Morris R.W., et al. Aspirin use in middle-aged men with cardiovascular disease are opportunities being missed? Br J Gen Pract. 47:1997;417-421
14. Willich S.N., Muller-Nordhorn J., Kulig M., et al. Cardiac risk factors, medication, and recurrent clinical events after acute coronary disease; a prospective cohort study. Eur Heart J. 22:2001;276-279
15. Stafford R.S. Aspirin use is low among United States outpatients with coronary artery disease. Circulation. 101:2000;1097-1101
16. Stafford R.S., Radley D.C. The underutilization of cardiac medications of proven benefit, 1990 to 2002. J Am Coll Cardiol. 41:2003;56-61
17. Jackevicius C.A., Mamdani M., Tu J.V. Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA. 288:2002;462-467
18. Benner J.S., Glynn R., Mogun H., et al. Long-term persistence in use of statin therapy in elderly patients. JAMA. 288:2002;455-461
19. Majeed A., Moser K., Maxwell R. Age, sex and practice variations in the use of statins in general practice in England and Wales. J Public Health Med. 22:2000;275-279
20. Wei L., Wang J., Thompson P., et al. Adherence to statin treatment and readmission of patients after myocardial infarction a six year follow-up study. Heart. 88:2002;229-233
21. Hunt D., Young P., Simes J., et al. Benefits of pravastatin on cardiovascular events and mortality in older patients with coronary artery disease are equal to or exceed those seen in younger patients results from the LIPID Study. Ann Intern Med. 134:2001;931-940
22. Flaker G.C., Warnicka J.W., Sacks F.M., et al. Pravastatin prevents clinical events in revascularized patients with average cholesterol concentrations. J Am Coll Cardiol. 34:1999;106-112
23. Campeau L., Hunninghake D.B., Knatterud G.L., et al. Aggressive cholesterol lowering delays saphenous vein graft atherosclerosis in women, the elderly, and patients with associated risk factors NHLBI post coronary artery bypass graft clinical trial. Post CABG Trial Investigators. Circulation. 99:1999;3241-3247
24. Popma J.J., Sawyer M., Selwyn A.P., et al. Lipid-lowering therapy after coronary revascularization. Am J Cardiol. 86:2000;18-28H
25. Mantel-Teeuwisse A.K., Verschuren V.M.M., Klungel O.H., et al. Undertreatment of hypercholesterolaemia: a population-based study. Br J Clin Pharmacol. 55:2003;389-397
26. Kirklin J.W., Akins C.W., Blackstone E., et al. Guidelines and indications for coronary artery bypass graft surgery a report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Subcommittee on Coronary Artery Bypass Graft Surgery). J Am Coll Cardiol. 17:1991;543-589
27. Yusuf S., Sleight P., Pogue J., et al. Effects of an angiotensin- converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients the Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 342:2000;145-153
28. Oosterga M., Voors A.A., Pinto Y.M., et al. Effects of quinapril on clinical outcomes after coronary artery bypass grafting (the QUO VADIS Study). Am J Cardiol. 87:2001;542-546
29. Kjoller-Hansen L., Steffenson R., Grande P. The Angiontensin-converting enzyme inhibition Post REvascularization Study (APRES). J Am Coll Cardiol. 35:2000;881-888
30. O'Keefe J.H., Wetzel M., Moe R.R., et al. Should an angiontensin- converting enzyme inhibitor be standard therapy for patients with atherosclerotic disease? J Am Coll Cardiol. 37:2001;1-8
31. Yusuf S., Held P., Furberg C. Update of effects of calcium antagonists in myocardial infarction or angina in light of the second Danish Verapamil Infarction Trial (DAVIT-II) and other studies. Am J Cardiol. 67:1991;1295-1297